The head of the Iranian Space Agency (ISA) says the strategic vision of the martyred Leader laid the foundation for the long-term development of the country's space industry.

By developing the Oncopore G2121, a domestically-produced electrochemotherapy (ECT) system featuring proprietary probe technology with no foreign analogues, Iran has joined the United Kingdom and Italy as one of only three nations worldwide capable of manufacturing this advanced cancer treatment device.

Iran's Martyr Soleimani Constellation, a 24-satellite narrowband IoT network, is set for launch beginning early 2027, showcasing the country's indigenous space technology, industrial-scale production, and strategic autonomy in space-based communications.

Iran joins elite ADC-producing countries with Tederox and Padynex, cutting costs by over 90 percent, expanding HER2-positive cancer treatment access, and showcasing rapid biopharmaceutical advancement despite sanctions.

Iran ranks fourth globally in high-impact research on advanced aircraft engines, including hypersonic propulsion, reflecting a focused, sanctions-resistant scientific strategy that has positioned it ahead of several traditional aerospace powers.

Iran’s space program is moving ahead with the upcoming launch of Pars-2 Satellite and Shahid Soleimani constellation deployment by year-end, says the Iranian minister of technology.

Iran has emerged as the leading scientific producer in microelectronics among Islamic countries, securing first place across most major branches of the field.